NEOPHARMED GENTILI acquired by ARDIAN

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs

The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring. The strategic rationale for the move centers on the acquirer's objective to provide integrated, data-driven health management solutions that complement its existing portfolio of vaccines and medicines

Ardian acquired a majority stake in Inula from Vendis Capital and founder Dominique Baudoux. The founder and Vendis Capital retained reinvestment options, while the CEO and the management team reinvested significantly to increase their equity stake. The acquisition aimed to leverage Ardian's global footprint to accelerate Inula's expansion in the US, Italy, and Germany, and to pursue buy-and-build opportunities in the fragmented aromatherapy market.

Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior. In this new capital structure, Naxicap Partners retains a significant minority interest, signaling continued confidence in the company's growth trajectory and industrial potential. The rationale for the transaction is rooted in HTL,s exceptional profitability and its unique position in a high-barrier-to-entry niche of the biotechnology sector

The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction

The acquisition of Acteon by Dentressangle represents a major turning point in the medtech’s trajectory, moving toward an aggressive buy-and-build strategy. The strategic rationale for this transaction centers on an "industrial-consolidation" play, merging the group’s industry-leading technical operational depth in ultrasonic surgery with the sponsor’s extensive expertise in executing international build-up operations. This structural alignment provides the organization with the institutional capital and strategic guidance required to address the increasing demand for integrated dental technology suites

The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets. The strategic rationale for the transaction centers on the fusion of Paragon Medical’s niche leadership in orthopedic instrumentation with NN, Inc

Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni). Permira's thesis was centered on accelerating Corin's international scale—particularly in the US and Australian markets—and fueling an aggressive buy-and-build strategy to integrate digital health and robotic capabilities into the core implant business. This approach aimed to position Corin as a "Challenger OEM" capable of disrupting larger incumbents through superior product innovation and data-driven patient monitoring

PerkinElmer, Inc. has entered into a definitive agreement to acquire 100% of EUROIMMUN Medical Laboratory Diagnostics. The transaction aims to significantly expand PerkinElmer's reach into the autoimmune and allergy diagnostic markets, while simultaneously strengthening its presence in China and other emerging markets. By combining EUROIMMUN’s expertise in immunology and infectious diseases with PerkinElmer's established leadership in reproductive health and genomic offerings, the merged entity will offer a more robust suite of diagnostic solutions globally

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.